Hildy Sastre's record includes successfully defending Sanofi-Aventis in two bellwether trials over its chemotherapy drug ...

A woman in her 70s presented with an eight month history of transverse nail changes affecting all fingernails and toenails. She had a history of breast cancer treated with mastectomy, followed by six ...

AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage ...

AstraZeneca’s Imfinzi in combo with standard-of-care FLOT chemotherapy gets European approval to treat patients with early gastric and gastroesophageal cancers: Cambridge, UK Tu ...

AstraZeneca AZN announced that the European Commission (EC) has approved its blockbuster cancer drug Imfinzi (durvalumab) as a perioperative treatment for early gastric and gastroesophageal junction ...

AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the European Union (EU) for the ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...

Imfinzi (durvalumab), in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel), has received EU approval. The perioperative immunotherapy was ...

The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study ...

Shenouda With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, ...

Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 ---- Interim systemic lung cancer ...

NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion ...